NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc. (“Pacira” or the “Company”) (NasdaqGS: PCRX) stock between April 9, 2012 and September 24, 2014.
For more information, click here: http://zlk.9nl.com/pacira-pharmaceuticals-pacira.
The complaint alleges that the Company misstated and/or failed to disclose that it: (a) overstated the efficacy of its product EXPAREL; (b) improperly promoted EXPAREL as able to work for up to 72 hours despite it being only approved for 24-hour pain relief; (c) improperly claimed EXPAREL as safe and effective for use in cholecystectomy and colectomy, though its approved labeling does not provide for such use; and (d) derives a substantial portion of its revenues from off-label marketing.
On September 25, 2014, the Company revealed it had received a Warning Letter from the FDA regarding the marketing of EXPAREL. Shares of Pacira closed at $106.28 per share the day before the announcement, and recently closed at just $98.35 per share on October 6, 2014.
If you suffered a loss in Pacira you have until December 2, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/pacira-pharmaceuticals-pacira.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.